Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry

Khattab, 2011, Management of hepatitis C virus genotype 4: recommendations of an international expert panel, J Hepatol, 54, 1250, 10.1016/j.jhep.2010.11.016 Wantuck, 2014, Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6, Aliment Pharmacol Ther, 39, 137, 10.1111/apt.12551 Ray, 2000, Genetic epidemiology of hepatitis C virus throughout Egypt, J Infect Dis, 182, 698, 10.1086/315786 Guerra, 2012, HCV burden of infection in Egypt: results from a nationwide survey, J Viral Hepat, 19, 560, 10.1111/j.1365-2893.2011.01576.x Frank, 2000, The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt, Lancet, 355, 887, 10.1016/S0140-6736(99)06527-7 Rao, 2002, Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt, BMC Infect Dis, 2, 29, 10.1186/1471-2334-2-29 Esmat, 2012, Treatment of chronic HCV genotype 4 infection, Curr Hepat Rep, 11, 250, 10.1007/s11901-012-0146-2 Muir, 2014, The rapid evolution of treatment strategies for hepatitis C, Am J Gastroenterol, 109, 628, 10.1038/ajg.2014.66 Lawitz, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853 Jacobson, 2013, Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, N Engl J Med, 368, 1867, 10.1056/NEJMoa1214854 American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org/>; 2014 [accessed 2.06.14]. 2014, EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol, 60, 392, 10.1016/j.jhep.2013.11.003 World Health Organization. Guidelines for screening, care and treatment of persons with hepatitis C infection. <http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/>; 2014. [published April 2014, accessed June 2, 2014]. Kirby, 2013, Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-infected adult subjects, Hepatology, 58, 746A Moreno, 2014, Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: SVR12 results of a phase III trial, J Hepatol, 60, S535, 10.1016/S0168-8278(14)61486-0 Hezode, 2014, Results from the phase 2 PEARL-I study: Interferon-free regimens of ABT-450/R + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection, J Hepatol, 60, S24, 10.1016/S0168-8278(14)60060-X Hassanein, 2014, All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection, J Hepatol, 60, S472, 10.1016/S0168-8278(14)61323-4 Roulot, 2007, Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection, J Viral Hepat, 14, 460, 10.1111/j.1365-2893.2006.00823.x Moucari, 2009, Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4, Gut, 58, 1662, 10.1136/gut.2009.185074 Dimitroulopoulos, 2010, European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response, Hepat Mon, 10, 193 Papastergiou, 2012, Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?, J Med Virol, 84, 1217, 10.1002/jmv.23324 Antaki, 2010, The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report, Liver Int, 30342 Asselah, 2012, IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C, J Hepatol, 56, 527, 10.1016/j.jhep.2011.09.008 Asselah, 2014, Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity, Liver Int, 34, 1447, 10.1111/liv.12599